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A B S T R A C T
Since tobacco remains a leading cause of global morbidity and mortality, emphasis needs to be given to pre-
ventive approaches to tobacco consumption. Environmental and policy strategies with fear appeals are im-
portant contributors to reductions in smoking prevalence. Fear appeals are persuasive messages—often using
graphic and emotionally evocative imagery and language—that attempt to scare their audiences into tobacco
cessation. While the intentions of fear appeals are benign, their effects are not necessarily so; here, we argue that
some fear appeals carry a significant risk of backfiring by eliciting nocebo effects among its viewers. In this
context, it is important to recognize that there is currently no justification for disregarding potential nocebo
effects. Therefore, we should improve our understanding of nocebo effects in the field of preventive medicine, as
well as the impact of strategies aimed at mitigating their negative health effects.
Introduction
One-hundred eighteen countries or jurisdictions currently mandate
the inclusion of pictorial warnings of tobacco-related harms on tobacco
and related products, which are often accompanied by equally strong
text warnings [1]. Studies indicate that these emotionally evocative
anti-tobacco campaigns constitute among the most cost-effective tools
for motivating the audience toward tobacco cessation [2]. Not sur-
prisingly, these “fear appeals” have become a central theme of many
tobacco-control campaigns and other persuasive communications; they
are found just about everywhere we look—from tobacco packages to
the television screens in our homes. Following the advent of these fear
appeals, tobacco consumers are now more adequately informed of the
health risks they face, including heart disease, stroke, erectile dys-
function, and lung cancer [3]. We propose, however, that environ-
mental and policy strategies using fear appeals, regrettably, compro-
mise full compliance with the principle of nonmaleficence (i.e., “do no
harm”) by disregarding potential nocebo effects completely without
justification.
Do some anti-tobacco strategies backfire?
Nocebo responses and subsequent effects are noxious changes in
individuals’ physiological conditions that are attributable to the overall
context surrounding any intervention (either active or inert), rather
than to the specific action of that intervention [4–6]. They are triggered
or exacerbated by both conscious and nonconscious mechanisms such
as outcome expectancies, associative learning processes, past experi-
ences, explicit emotions, and social cues [4–6]. Although most health-
care providers now recognize that nocebo effects contribute to per-
ceived side effects, poor medication adherence, and a diminished sense
of well-being in clinical practice [6,7], few would consider the possi-
bility of nocebo effects adversely influencing the effectiveness of en-
vironmental and policy strategies with fear appeals for preventive
purposes. However, we argue that these well-intended interventions
may create—or at least reinforce—negative outcome expectancies
through insistent connection of tobacco consumption with its related
harms, which are somewhat fatalistic in nature and often lacking
nuance, strong emotional arousal elicited by graphic images and lan-
guage, negative framing of prevalence data causing overestimation of
the risk by the viewer, and conditioned associations (Fig. 1). It is critical
to note, however, that we do not intend to question or seek to
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undermine the importance and consequences of tobacco cessation. Let
us be clear—tobacco consumption can and does cause harm [8–10];
however, the message should not be delivered via nocebogenic fear
appeals.
Are some tobacco-related harms more nocebo-prone than others?
Presumably, our proposition is more likely to be considered for
“non-specific” tobacco-related harms with fluctuating courses than for
“somatic” harms (e.g., erectile dysfunction vs lung cancer). Indeed, a
series of studies has provided evidence on the relationship between
disclosure of medication side effects and the incidence of erectile dys-
function. In one study, blinded administration of finasteride was asso-
ciated with a significantly higher overall incidence of erectile dys-
function in men with benign prostatic hyperplasia (N = 107) who were
informed about the potential sexual side effects (“…it may cause
erectile dysfunction, decrease libido, problems of ejaculation; but, it is
uncommon”), as compared to those who were omitted from disclosure
(30.9% vs 9.6%, respectively; p = .02) [11]. In another study, 96 men
were prescribed beta-blocker therapy (atenolol) and randomized into
three groups with distinct degrees of information disclosure. The first
group that was not told what drug they were taking reported a 3.1%
incidence of erectile dysfunction, whereas the groups knowing that they
were receiving a beta-blocker reported a 31.2% and 15.6% (p < .01)
incidence of erectile dysfunction, depending on the fact if they were or
were not informed on the potential side effect of erectile dysfunction,
respectively (“… it may cause erectile dysfunction; but, it is un-
common”) [12]. These findings were confirmed in an independent
study with similar design involving the use of metoprolol [13].
Much can be learned from these three elegant and innovative re-
ports; they demonstrate that information disclosure about the risk of
erectile dysfunction is not merely an abstract speculative warning; ra-
ther, it can independently be self-fulfilling. There is little reason to
believe that the legally obligated image of a deeply worried man and
the statement, “Smoking increases the risk of impotence” on European
tobacco products, for example, does not elicit a similar nocebo effect
among the about 55 million male smokers in the European Union.
Given that similar emotionally evocative health warnings about im-
potence are in place in many other countries around the world, in-
cluding Brazil, Canada, Egypt, the Russian Federation, and Thailand
[14], nocebogenic fear appeals pose a global problem.
One might be more reluctant, however, to consider this postulate for
“somatic” tobacco-related harms, even though placebo—nocebo’s
benevolent twin—was shown to improve treadmill-induced ST-segment
depression [15], motor function in Parkinson’s Disease [16–19], and
various other clinical outcomes beyond subjective perceptions of
quality [17]. That aside, one might argue that lung cancer, for instance,
differs from subjective responses. It has to do with the growth of cancer
cells initiated by mutations and epigenetic changes that activate on-
cogenic drivers. There cannot be a nocebo effect in lung cancer devel-
opment, can there? Though many, if not most, would dismiss this ap-
parent paradox of increased lung cancer risk as mere philosophical
speculation, proponents would note that it might not be completely
impossible, since nocebos and oncogenesis involve common biochem-
ical pathways. In defense of the latter, it should be noted that beha-
vioral conditioning of the neuroendocrine and immune system (e.g.,
cortisol, IL-2, IFN-γ, and lymphocytes) has been repeatedly demon-
strated since its first report in 1886 [17,20–24]. Perhaps such tumor
environmental changes would suffice for shifting the delicate (im-
munoediting) equilibrium from cancer cell elimination to escape [25]?
Further, the repeated admonitions that smoking is self-destructive
could increase psychological stress levels in continuing smokers [26].
From both animal and clinical studies, there are extensive data con-
cerning the contributions of stressors to diverse (objective) pathophy-
siological processes, including cancer development and progression,
altered DNA repair, angiogenesis, immune tolerance, and metastasis
[27,28].
Experimental considerations
Assessing the impact of nocebo effects on rates of tobacco-related
harms is not an easy undertaking and may require different study de-
signs depending on the harm being studied. Some understanding could
be gained by analyzing longitudinal data from large cohorts, using well-
defined diagnostic criteria and confounding adjustment. Using a time-
dependent approach, hazard ratios for harm incidence can be calcu-
lated and compared. An onset of increasing hazard beginning soon after
implementation of the fear appeal, would lend support to our hypoth-
esis. Unfortunately, such adequate high-quality data are rare and/or
costly to obtain.
Fig. 1. Logic Flow Diagram.
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The currently accepted assumption that changes in cigarette design
(e.g., the addition of filters) are responsible for the increased lung
cancer risk in smokers over the past decades is actually based on this
type of evidence, complemented by some toxicology data [29]. Inter-
estingly—and provocatively, changes in cigarette design were im-
plemented synchronously with the first health warnings on cigarette
packages (1966 in the USA) [30]. It is tempting to question whether this
observed increased risk can be explained by a nocebo effect due to
environmental and policy strategies using fear appeals (even if to
a—very—discrete extent). In our opinion, there is no definite answer to
that question, at least not without more research addressing this spe-
cific question. Perhaps not; however, is it not plausible enough to
consider?
Experimentally, one could design a trial in which clusters of smo-
kers (e.g., cigarette shops) are randomized to exposure to either erectile
dysfunction or non-erectile dysfunction fear appeals only, in which
baseline and post-exposure erectile dysfunction prevalence are com-
pared. However, in addition to being ethically fraught, such trial might
be confounded by (nocebogenic) information input from other sources
(e.g., internet).
A note of caution is in place here, as the nocebo effect size may not
only be dependent on the way the environmental or policy strategy is
communicated (e.g., strongly emotionally evocative fear appeals vs.
emotionally neutral strategies) or the harm in question (e.g., erectile
dysfunction vs. lung cancer), but also on the characteristics of the
viewer. In fact, as is often the case, the most vulnerable may be among
those who disproportionately have to bear the unintended adverse
consequences of policy initiatives [31,32]. First, the literature per-
taining to risk factors that contribute to nocebo effects have identified
several nocebo-prone personality traits, including type A personality,
lower positive affect, pessimism, neuroticism, and somatization [33]; of
these, some might, in turn, be associated with higher smoking pre-
valence [34,35]. Second, at an international level, although many low-
to middle-income countries are currently implementing tobacco health
warnings with fear appeals [1,14], they are encountering a relatively
steady increase, rather than a decrease, in tobacco consumption pre-
valence which in turn increases the population at risk [36]. Together,
these findings suggest that the nocebo burden of environmental and
policy strategies with fear appeals is theoretically much greater in
vulnerable populations. This should be a matter of high priority in fu-
ture research.
Conclusion and recommendations
The moral of this Article is not just that the nocebo effect is in-
escapably real, but that it has significant public health ramifications,
which have never been properly considered within the field of tobacco
control. Thus, the question arises: how should this Article influence
clinical practice? Given that fear appeals are increasingly used to mo-
tivate tobacco cessation globally and based on the findings concerning
information disclosure about the risk of erectile dysfunction, we would
strongly urge our respective governments and public health bodies to
take robust action against fear appeals stating that smoking causes
impotence, in effort to reverse the deleterious impact on millions of
male smokers worldwide due to a nocebo effect. For other tobacco-
related harms (e.g., cancer, heart disease, stroke, etc.), however, the
available evidence is more circumstantial, and simply omitting en-
vironmental and policy strategies with fear appeals altogether could
potentially undermine some advantageous public health missions
(Fig. 2). Regardless, even in this context, we urge extreme caution in
the use of fear appeals—will we continue to violate the precautionary
principle by potentially exposing remaining smokers to further liabi-
lity?
What else should be done to reduce unnecessary suffering and avoid
potentially harmful preventive interventions? Various strategies may
mitigate the potential threat of a nocebo effect posed by environmental
and policy strategies with fear appeals. First, alternative approaches
that are scientifically established as being (highly) effective but less
morally conflicted, such as increased tobacco taxation and smoking
bans in public spaces [37], should be preferred over fear appeals as it is
in the mutual interest of society and the individuals concerned. Second,
acknowledging that fear appeals are a potential nocebo gives policy-
makers the additional responsibility of actively considering if the
probable benefits of the fear appeal outweigh infringed ethical norms,
such as the precautionary and nonmaleficence principles and any
probable nocebo effects (Fig. 2). Third and finally, longitudinal data
with a sufficient sample size, preferably involving well-defined diag-
nostic criteria and reasonable confounding adjustment, are warranted
to verify the conclusions presented here (as discussed above), with the
eventual aim to develop and adopt, at the national and international
level, comprehensive evidence-based tobacco control strategies that
consider the nocebo effect. Lessons from the past can be applied to
motivate such future research. The once widespread perceptions—often
based on unblinded clinical experience—that arthroscopic debridement
of the knee, vertebroplasty, and percutaneous coronary intervention
unquestionably improve osteoarthritis [38], vertebral fracture [39],
and angina [40], respectively, were all demonstrated not to correspond
to reality. Double-blind sham-controlled trials revealed that the ob-
served differences are attributable to a placebo effect whereas the in-
terventions themselves are lacking true efficacy. Creative (perhaps
unusual) thinking and audacious experimental research was what was
needed to expose the placebo effect and prove conventional wisdom
wrong.
Although our Article focused on fear appeals, and more specifically
on tobacco control, similar findings may be present with fear appeals
targeting other risky behaviors (such as alcohol and marijuana con-
sumption), as well as other preventive health communications without
fear appeals. Because the way information is communicated to in-
dividuals has the potential to change reality, as has been suggested by
many and neglected by more [41], it is vital to take great care in how
information is disclosed in all areas of clinical practice as well as in
policy setting.
In conclusion, we argue that since nocebo responses and subsequent
effects to environmental and policy strategies with fear appeals are
plausible, we should improve our understanding of nocebo effects in the
context of preventive medicine, as well as the impact of strategies
aimed at mitigating the negative health effects connected with fear
appeals. The message we deliver and the way we deliver it should have
the least potential to cause harm and the greatest potential to suc-
cessfully motivate behavior change.
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Fig. 2. Benefit-Risk Ratio of Fear Appeals. It has been
consistently noted that the amount of fear (i.e., high
depicted disease severity) in the message’s content is
positively correlated with motivation for behavior
change. Generally speaking, the more severe a dis-
ease, the less impact of psychological factors on its
course, and, the more it will scare individuals (e.g.,
lung cancer). Taken together, we hypothesize that
the benefit-risk ratio of fear appeals is modulated by
the impact of psychological factors on disease course,
encompassing a spectrum. For tobacco-related harms
at one end of the spectrum (area A), characterized by
a low impact of psychological factors (e.g., lung
cancer; “somatic harms”), fear appeals could be in-
dicated because they probably have an advantageous
benefit-risk ratio. For tobacco-related harms at the
other end of the spectrum (area C), characterized by
a high impact of psychological factors (e.g., erectile
dysfunction; “non-specific harms”), fear appeals
should be omitted since they could do more harm
than benefit. It is critical to note that although some
fear appeals might very well be beneficial to the so-
ciety as a whole (because they effectively motivate
behavior change; e.g., lung cancer fear appeals), for
the individuals that continue smoking despite the
many efforts of public health bodies, only the nocebo
effect will remain—without benefit, by definition.
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